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ABSTRACT
Albumin is a remarkable carrier protein with multiple cellular receptor and ligand binding sites, which
are able to bind and transport numerous endogenous and exogenous compounds. The development
of albumin-bound drugs is gaining increased importance in the targeted delivery of cancer therapy.
Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal
metastasis (PM). PM is characterized by the presence of widespread metastatic tumor nodules on the
peritoneum, mostly originating from gastro-intestinal or gynaecological cancers. Albumin as a carrier
for chemotherapy holds considerable promise for IP delivery in patients with PM. Data from recent
(pre)clinical trials suggest that IP albumin-bound chemotherapy may result in superior efficacy in the
treatment of PM compared to standard chemotherapy formulations. Here, we review the evidence on
albumin-bound chemotherapy with a focus on IP administration and its efficacy in PM.
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1. Introduction
The efficacy of a drug is dependent on the accumulation at
the target site with a concentration and frequency that maxi-
mizes the therapeutic effectiveness and minimizes side-
effects to the patient. Systemic chemotherapy is relatively
inefficient in PM due to poor vascularity of the metastatic
tumor nodules on the peritoneum (Tempfer, 2015; Winner
et al., 2016). While IP drug delivery has been firmly estab-
lished as a treatment option in patients with PM, clinical
treatment has to rely on off-label use of drugs that were
developed and approved for IV treatment. IP chemotherapy
is based on the dose intensification provided by the delivery
of chemotherapy into the peritoneal cavity and the delayed
clearance caused by the peritoneal plasma barrier (Flessner
et al., 1985; Dedrick & Flessner, 1997). Because of their activ-
ity profile, the taxanes are ideal candidates for IP administra-
tion. The potential of solvent-based paclitaxel (Sb-PTX,
TaxolTM) for IP administration is, however, limited by the
local toxicity and potential of hypersensitivity reactions asso-
ciated with the Cremophor ELTM solvent. Albumin-bound
drug delivery has been utilized to overcome these obstacles.
Nanoparticle albumin-bound paclitaxel (Nab-PTX, AbraxaneVR )
was developed and demonstrated superior antitumor activity
and less side-effects compared to Sb-PTX (Kinoshita et al.,
2014). Likewise, methotrexate (MTX), 5-fluorouracil (5-FU),
docetaxel and doxorubicin (DOX) were bound to albumin to
improve the pharmacokinetics and pharmacodynamics of the
drugs (Burger et al., 2001; D’Cruz et al., 2010; Maltas et al.,
2016; Sharma et al., 2017). In theory, any cancer drug may
be delivered IP but it is rational to explore IP delivery of
albumin-bound chemotherapy. Cancers such as ovarian and
pancreatic cancer express high levels of secreted protein
acidic and rich in cysteine (SPARC), an albumin-binding 42-
kDa matricellular glycoprotein whose expression in tumor
interstitium correlates inversely with overall survival (Von
Hoff et al., 2011). Albumin is a remarkable carrier with mul-
tiple cellular receptor and ligand binding sites, which pro-
motes the delivery of chemotherapy in cancer cells. Here, we
review albumin-bound cytostatics and their application in
IP therapy.
2. The anatomy of the peritoneum
The peritoneal cavity is contained within two leaves of a
serosal membrane. The parietal peritoneum covers the
abdominal wall, the pelvis, the anterior surfaces of the retro-
peritoneal organs and the inferior surface of the diaphragm,
while the visceral peritoneum lines the intra-abdominal organs
and mesenteries (Flessner, 2005). The total serosal exchange
surface of the peritoneum is 1.5 m2 on average (Esquivel,
2010). Figure 1 illustrates the histology of the peritoneum. The
peritoneum consists of a monolayer of flattened, squamous-
like or cuboidal mesothelial cells supported by a basement
membrane, a submesothelial connective tissue layer, and an
underlaying cellular and associated microvessel network
(Flessner, 2005; Mutsaers et al., 2016; Dakwar et al., 2017).
In normal conditions, the mesothelial cells are intercon-
nected by tight junctions. On the apical surface of mesothe-
lial cells, microvilli and cilia are present, which are covered in
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a glycocalyx consisting of proteoglycans and glycosaminogly-
cans. This glycocalyx secretes surface hyaluronan. As such, the
mesothelial cells provide a non-adhesive surface and function
as a barrier against physical damage (Flessner, 2005; Dakwar
et al., 2017). On the subdiaphragmic peritoneal surface, lymph-
atic portals named stomata are abundantly present and inter-
rupt the continuity of the mesothelial membrane. Stomata are
located around the milky spots, maintaining a connection
between the peritoneal cavity and the lymphatic system (van
Baal et al., 2017). Mesothelial cells are anchored to the subme-
sothelial basement membrane, the main components of which
are collagen type IV and laminin. Mesothelial cells express b1
integrins to attach to the submesothelial basement membrane
via laminin. The mesothelium is supported by submesothelial
stroma through an extracellular matrix, consisting of collagen,
fibronectin, glycosaminoglycans, and proteoglycans (van Baal
et al., 2017).
PM occurs after a sequence of events, called the peritoneal
metastatic cascade. After the metastatic tumor cells reach the
peritoneal cavity, they are mobilized by the transport flow of
peritoneal fluid. The adhesion of tumor cells might occur at
several components of the peritoneum. The glycocalyx, meso-
thelial cell or the underlying stroma are targets for tumor cell
adhesion. Tumor cells will breach the basement membrane
after direct contact at places where the mesothelium is natur-
ally discontinuous such as milky spots or disrupted by trauma,
or due to mechanisms by which the tumor cell is able to
denude the basement membrane. Further invasion of tumor
cells is dependent on enzymatically degrading the extracellu-
lar matrix by matrix metalloproteinases (Sluiter et al., 2016).
Peritoneal microvessels are hyperpermeable and pro-inflam-
matory cytokines and chemokines are secreted, leading to an
oncotic pressure toward the peritoneal cavity. Tumor cells also
induce apoptosis of the mesothelial cells leading to an altered
structure of the peritoneal membrane (Flessner, 2005; Ceelen
& Bracke, 2009; Sandoval et al., 2013).
PM is a manifestation characterized by the presence of
widespread metastatic tumor nodules on the peritoneum
(Figure 2), originating from gastro-intestinal or gynaeco-
logical cancers (Coccolini, 2013). A small group of patients is
eligible for surgical removal of all tumor nodules (debulking)
combined with intraoperative chemoperfusion (Al Rawahi
et al., 2013; Oseledchyk & Zivanovic, 2015). However, many
patients present with irresectable disease, which has a dismal
prognosis. Survival in patients with irresectable peritoneal
metastases from colon cancer is 15 months, from gastric can-
cer 4 months and from pancreatic cancer only 6 weeks
(Klaver et al., 2012; Thomassen et al., 2013; 2014). Systemic
chemotherapy is relatively inefficient in PM due to poor vas-
cularity of peritoneal tumor nodules (Tempfer, 2015; Winner
et al., 2016).
3. Intraperitoneal drug delivery
3.1. The rationale for locoregional treatment
Locoregional therapy is based on the dose intensification
provided by the administration of chemotherapy into the
peritoneal cavity and the delayed clearance caused by the
peritoneal plasma barrier (Flessner et al., 1985; Dedrick &
Flessner, 1997). Figure 3 gives an overview of strategies for
IP drug delivery. In addition to the conventional catheter-
based strategy, metronomic dosing represents a novel
approach defined as the frequent and continuous administra-
tion of conventional chemotherapy at low doses without
drug-free breaks (Andre et al., 2014). Thermosensitive hydro-
gels containing drugs are another option for IP drug delivery.
Hydrogels are liquid at room temperature but will form a gel
at body temperature, leading to a prolonged exposure time
(Fan et al., 2015). Another option involves intraoperative che-
moperfusion (IPEC), immediately after cytoreductive surgery.
Intraoperative chemoperfusion is usually performed under
Figure 1. Structure of the peritoneum and underlying layers. The mesothelial monolayer covers the basement membrane and is supported by the submesothelial
stroma. 1: stomata; 2: microvilli covered with a glycocalyx; 3: flattened mesothelial cell; 4: cuboidal mesothelial cell; 5: intercellular junction, mainly tight junction;
6: b1 integrin attached to basement membrane via laminin; 7: laminin and collagen IV fibers; 8: submesothelial stroma; 9: collagen, fibronectin, glycosaminoglycans
and proteoglycans fibers; 10: fibroblast; 11: macrophage; 12: capillary; 13: lymphatic vessel.
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hyperthermic conditions (HIPEC) (Ceelen & Flessner, 2010). A
recent method of IP drug delivery is pressurized intraperito-
neal aerosol chemotherapy (PIPAC), which is performed dur-
ing laparoscopy. The cytotoxic solution is injected under a
maximal pressure of 20 bar, and the resulting aerosol is dis-
persed in the abdomen (Solass et al., 2014).
The peritoneal plasma barrier ensures a pharmacokinetic
advantage leading to higher achievable IP concentrations
whilst minimizing systemic toxicity (Dedrick et al., 1978;
Dedrick & Flessner, 1997; Hasovits & Clarke, 2012). IP treat-
ment also increases the drug concentration in the vicinity of
avascular minimal peritoneal tumor nodules, which are diffi-
cult to eradicate with systemic chemotherapy (Dakwar et al.,
2017). The pharmacokinetic advantage of IP drug delivery is
usually expressed as the ratio of the area under the concen-
tration-time curve (AUC) in the peritoneal over the plasma
compartment (AUCIP/AUCplasma) and ranges widely from 2 to
1000 depending on the drug (Hasovits & Clarke, 2012; Carlier
et al., 2017).
3.2. Ideal drugs for IP administration
The peritoneal barrier is a complex three-dimensional struc-
ture. Contrary to intuition, the mesothelial lining is not the
main transport barrier, but the capillary walls and the sur-
rounding interstitium are the most important barriers for the
transport from the abdominal cavity to plasma (Flessner,
2005). Transport through the peritoneum was described by a
mathematical formula where both plasma and the peritoneal
cavity are considered as a single compartment separated
from each other by an effective membrane:
rate of mass transfer ¼ PA ðCp  CBÞ
with PA the permeability area (effective contact area x per-
meability), Cp drug concentration in the abdominal cavity
and CB drug concentration in the blood (Dedrick & Flessner,
1997). The traditional two-compartment model of peritoneal
transport describes transport of a drug from the peritoneal
cavity to the blood crossing the peritoneal membrane,
Figure 2. Irresectable peritoneal metastasis (white stars) in right upper abdomen (A) and left upper abdomen (B).
Figure 3. Overview of the strategies for IP drug delivery. IP: intraperitoneal; PIPAC: pressurized intraperitoneal aerosol chemotherapy; HIPEC: hyperthermic intraper-
itoneal chemotherapy. Figure adapted from Dakwar et al. (2017).
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indicating that large molecular weight substances would be
cleared more slowly from the peritoneal cavity than from the
systemic circulation. This would increase drug exposure to
the peritoneal tumor implants. The peritoneal clearance is
inversely proportional to the square root of the molecular
weight of the drug resulting in a higher concentration in the
peritoneal cavity than in plasma after IP administration
(Flessner et al., 1985).
Drugs that slowly exit the peritoneal cavity and that are
rapidly metabolized during first passage through the liver,
are more likely to exhibit a favorable pharmacokinetic advan-
tage for cavity exposure after locoregional delivery, com-
pared to drugs that do not exhibit these properties. Similarly,
a biologically active drug, which is rapidly cleared from the
systemic circulation after it enters the vascular compartment,
will show a more favorable advantage than one that is
slowly removed (either by metabolization into a nontoxic
metabolite or elimination from the body by excretion
through the kidneys). The drugs demonstrating the greatest
difference between cavity and systemic exposures are drugs
known to undergo extensive metabolism in the liver, e.g. 5-
fluorouracil (5-FU), doxorubicin (DOX), cytarabine, paclitaxel
(PTX), mitoxantrone (Kaplan et al., 1985; Goodman
et al., 2016).
Unique toxicities must be considered with regional cyto-
toxic drug delivery. The peritoneal lining can be sensitive to
the effects of cytotoxic drugs, leading to abdominal pain,
sclerosis, and subsequent bowel obstruction (Kaplan et al.,
1985; Walker et al., 2006; Graversen et al., 2018). Therefore,
even if a drug is known to be active against the tumor type
in question and preclinical models suggest promising
pharmacokinetics and antitumor efficacy, clinical IP delivery
may turn out to be precluded due to local toxic effects.
Table 1 provides an overview of the ideal drug character-
istics for IP delivery. Recently, results from preclinical and
early clinical trials have suggested that IP delivery of albu-
min-bound drugs may result in superior efficacy in the treat-
ment of PM compared to the standard solvent-based
formulation, whilst minimizing toxic side-effects (Kinoshita
et al., 2014; Carlier et al., 2018; Cristea et al., 2019).
4. Albumin-based drug delivery
4.1. Properties of albumin
Albumin is the most abundant plasma protein in human
blood with a concentration of 35–50mg/mL and a molecular
weight of 66.5 kDa. Albumin is synthesized in the liver hepa-
tocytes with approximately 10–15 g of albumin produced
and released in the vascular space daily (Larsen et al., 2016;
Hoogenboezem & Duvall, 2018). When albumin extravasates
into tissue, it is returned to the vascular space via the lymph-
atic system through a natural recycling mechanism.
Interaction with cellular receptors is responsible for albumin’s
cellular uptake and recycling. Albumin is known to be a car-
rier of a wide variety of both endogenous and exogenous
compounds owing to its hydrophobic binding pockets
(Kragh-Hansen, 1981). This facilitates the colloidal solubiliza-
tion and transport of hydrophobic molecules such as fatty
acids and steroids as well as different drugs. Furthermore,
the surface of albumin is negatively charged making it highly
water-soluble (Curry et al., 1998; Hoogenboezem &
Duvall, 2018).
4.2. Albumin binding strategies
Structurally, albumin contains three homologous alpha hel-
ical domains I, II and III (Figure 4). Each domain is comprised
of two subdomains A and B, which comprise four and six
alpha-helices, respectively. Its seven fatty acid binding sites
are distributed asymmetrically across the protein. Additional
important binding sites include the free thiol located at the
cysteine-34 amino acid residue and Sudlow’s sites I and II,
which bind a variety of hydrophobic drugs. Of interest to the
design of albumin-binding drugs is the distinct affinity and
nature of each of these binding sites (Arroyo et al., 2014;
Hoogenboezem & Duvall, 2018).
Hoogenboezem et al. defined two general binding strat-
egies: preformed albumin therapeutics and in situ binders.
Drugs that are categorized as in situ binders can dock on to
circulating (endogenous) albumin after these drugs were
delivered into the body. This facilitates transport, circulation
time in blood and solubilization of hydrophobic drugs such
as ibuprofen, diazepam, and warfarin (Kratz, 2008). In pre-
formed formulations, (exogenous) albumin is attached to the
drug prior to administration in the patient. Albumin was
hereby isolated from human donors (human serum albumin;
HSA), from bovine donors (bovine serum albumin; BSA) or
recombinantly produced. As such, preformed formulations
rely on drug loading into or attachment to exogenous albu-
min (Sjobring et al., 1988; Hoogenboezem & Duvall, 2018).
This discussion will focus on exogenous albumin-based can-
cer therapeutics since in situ binders are not suitable for IP
administration. Table 2 provides an overview of exogenous
albumin-based cancer therapeutics. Based on the albumin
binding strategy, exogenous albumin-based cancer therapeu-
tics can be divided in micro- or nanoparticle formulations,
covalent conjugations and genetic fusions (Figure 5).
4.3. Albumin-bound anticancer therapeutics
4.3.1. Micro- or nanoparticle formulations
A method that utilizes albumin as a carrier for cancer thera-
peutics involves drug encapsulation into an exogenous albu-
min-based particle. The methods for synthesizing albumin
Table 1. Ideal drug characteristics for IP delivery (Helm & Edwards, 2007).
An ideal drug for IP delivery has the following characteristics:
 inherent activity in the tumor type being treated;
 preclinical evidence for enhanced cytotoxicity associated with increasing
either (or both) the peak concentration or total AUC versus time curve;
 not toxic to the peritoneal lining;
 extensively and rapidly metabolized to a nontoxic form during initial
passage through the liver;
 quickly cleared after entry from the peritoneal cavity into the systemic
compartment;
 drug does not require metabolism in the liver to become an active
cytotoxic agent.
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particles can be generally categorized into the techniques of
desolvation, emulsification, thermal gelation, nano-spray dry-
ing and self-assembly (An et al., 2014; An & Zhang, 2017;
Hoogenboezem & Duvall, 2018).
Nab-technology is a patented novel nanotechnology-
based drug delivery platform developed by Abraxis
BioScience (currently under tradename Celgene, New Jersey,
United States), which exploits the natural properties of albu-
min to achieve a safe, solvent-free, efficient and targeted
drug delivery (Desai, 2008). Nab-PTX is approved by the
United States Food and Drug Administration (FDA) and
European Medicines Agency (EMA) for intravenous (IV) treat-
ment of metastatic breast cancer, locally advanced or meta-
static non-small cell lung cancer, and metastatic pancreatic
cancer in combination with gemcitabine (Desai, 2008;
Gardner et al., 2008; Von Hoff et al., 2011). Nab-rapamycin
was developed to treat non-muscle invasive bladder cancer
and Nab-docetaxel proved to be effective against prostate
and metastatic breast tumors (Desai, 2008; ClinicalTrials.gov,
2019b,c). Nab-CY196 is a novel albumin nanoparticle (NP)
docetaxel analog with an improved activity and safety profile
compared to Nab-docetaxel (D’Cruz et al., 2010). Another
albumin-based NP contains the Hsp90 inhibitor 17-allyla-
mino-17-demethoxygeldanamycin (17-AAG). A phase I trial
(NCT00820768) was planned with this therapeutic in combin-
ation with Nab-PTX for advanced non-hematologic malignan-
cies, but the study was withdrawn prior to enrollment for an
unknown reason (Desai, 2008; Larsen et al., 2016). Nab-5404
comprises a novel thiocolchicine dimer that possesses dual
inhibition of tubulin polymerization and topoisomerase I
activities and exhibits antiangiogenic and vascular targeting
activities leading to cytotoxic efficacy against solid tumors
and lymphomas (Desai, 2008; ClinicalTrials.gov, 2019a). This
exhaustive list of drugs based on Nab-technology is currently
under research.
In addition to the drugs formulated by Abraxis Bioscience,
many other labs have experimented with the delivery of
hydrophobic small-molecule anticancer drugs using albumin
particles. In 2011, Kim et al. (2011) fabricated a curcumin
(CCM)-loaded HSA NP using Nab-technology. Curcumin is a
pharmacologically active polyphenolic compound present in
Curcuma longa (turmeric) and is traditionally used as a nat-
ural spice. CCM inhibits nuclear factor-kappa beta (NF-jb),
which is involved in the pathogenesis of several malignan-
cies and inhibits production of cytokines such as tumor
necrosis factor a (TNF-a) and interleukin-1b (IL-1b). In vitro
and in vivo studies have shown cytotoxicity against colon
and pancreatic tumor cells. In 2016, a co-loading of PTX and
CCM via Nab-technology using high-pressure homogeniza-
tion was described. The PTX/CCM albumin NPs demonstrated
in vitro anti-tumor efficacy against pancreatic cancer cells
(Mia Paca-2 cells) (Kim et al., 2016). Co-encapsulation of CCM
and doxorubicin (DOX) in albumin NPs was tested on MCF-7
resistant breast cancer cells. DOX/CCM albumin NPs blocked
the adaptive treatment tolerance of cancer cells and elicited
efficient cell killing (Motevalli et al., 2019). Similarly, lapatinib-
loaded HSA NPs were described by Wan et al. (2016).
Lapatinib is a selective small-molecule dual-tyrosine kinase
inhibitor (TKI) of the human epidermal growth factor recep-
tor 2 (HER2) and the epidermal growth factor receptor
Figure 4. Cristal structure of HSA (PDB ID 1AO6). Albumin contains three homologous alpha helical domains I, II and III. Each domain is comprised of two subdo-
mains A and B, which comprise four and six alpha-helices, respectively. Additional important binding sites include the free thiol located at the cysteine-34 amino
acid residue and Sudlow’s sites I and II.
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(EGRF). Lapatinib loaded HSA NPs showed in vivo efficacy
against triple negative breast cancer and also prevented
breast cancer metastasis to the brain. 5-FU was conjugated
to polyethylene glycol (PEG) anchored recombinant HSA
(rHSA) NPs (5-FU-rHSA-PEG-NPs). Preclinical in vitro experi-
ments suggested improved cytotoxicity and pharmacokinetic
profiles compared to 5-FU using a human colon cancer cell
line (HT-29) (Sharma et al., 2017).
Albumin NPs can be decorated with a variety of targeting
ligands to give additional specificity to cancer cell-associated
receptors. For instance, anti-cancer drugs were loaded into
mannosylated bovine serum albumin (BSA) NPs to target
drug-resistant colon cancer cells and tumor-associated mac-
rophages, which both highly express mannose receptors and
SPARC (Zhao et al., 2017). Likewise, folate-decorated BSA NPs
were developed for the targeted delivery of PTX to exploit
Table 2. Overview of exogenous albumin-based cancer therapeutics.
Anti-tumoral compound Drug name(s)
Binding
strategy Albumin Clinical status IP delivery References
5-Fluorouracil 5-FU-rHSA-PEG-NP Nanoparticle rHSA Preclinical in vitro – (Sharma et al., 2017)
17-Allylamino-17-
demethoxygeldanamycin
ABI-010, Nab-17AAG Nanoparticle HSA Withdrawn prior to phase
I trial
– (Desai, 2008; Larsen
et al., 2016)
Curcumin BSA-CCM Covalent BSA Preclinical in vitro – (Sun et al., 2014)
Curcumin HSA-CCM Nanoparticle HSA Preclinical in vivo – (Kim et al., 2011; 2016)
Docetaxel ABI-008, Nab-docetaxel Nanoparticle HSA Phase I/II trial – (Desai, 2008;
ClinicalTrials.gov,
2019b)
Docetaxel ABI-013 Nanoparticle HSA Preclinical in vivo – (D’Cruz et al., 2010)
Doxorubicin GA-rHSA-DOX Nanoparticle rHSA Preclinical in vivo – (Qi et al., 2015)
Doxorubicin L-HSA-DOX Covalent L-HSA Preclinical in vivo – (Di Stefano et al., 2008)
Doxorubicin Sp-HSA-DOX Microparticle Sp-HSA – – (Maltas et al., 2016)
Lapatinib – Nanoparticle HSA Preclinical in vivo – (Wan et al., 2016)
Methotrexate HSA-MTX Covalent HSA Phase II trial preclinical in vivo (Hartung et al., 1999;
Burger et al., 2001; Vis
et al., 2002)
Paclitaxel ABI-007, Nab-paclitaxel,
AbraxaneVR
Nanoparticle HSA FDA and EMA
approved (IV)
phase I/II trial (Desai, 2008; Gardner
et al., 2008; Xiao et al.,
2009; Von Hoff et al.,
2011; Coccolini, 2013;
Kinoshita et al., 2014;
Kim et al., 2016; Carlier
et al., 2018; Van De
Sande et al., 2018;
Cristea et al., 2019)
Proaerolysin – Genetic fusion HSA Preclinical in vivo – (Pruitt et al., 2016)
Rapamycin ABI-009, Nab-rapamycin Nanoparticle HSA Phase II trial – (Desai, 2008;
ClinicalTrials.gov, 2019c)
Recombinant interleukin-2 Albuleukin, rHSA-rIL-2 Genetic fusion rHSA Phase I trial preclinical in vivo (Osborn et al., 2004;
Melder et al., 2005)
Thiocolchicine dimer ABI-011, Nab-5404 Nanoparticle HSA Phase I trial – (Desai, 2008;
ClinicalTrials.gov, 2019a)
Figure 5. Albumin binding strategies. An example of an IP delivered drug per binding strategy is provided (Burger et al., 2001; Desai, 2016).
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overexpression of the folate receptor by a wide range of
tumor cell types (Zhao et al., 2010). The glycyrrhetinic acid
(GA) receptor is overexpressed in liver cancer cells.
Consequently, GA modified rHSA NPs were developed to tar-
get liver tumor cells. Qi et al. encapsulated GA-rHSA NPs
with DOX (GA-rHSA-DOX) and demonstrated increased cyto-
toxic activity in liver tumor cells compared to non-targeted
NPs (rHSA-DOX) (Qi et al., 2015). Albumin NPs can also be
decorated with antibodies such as DI17E6, a monoclonal
antibody directed against av integrins, which are cell mem-
brane-spanning matrix adhesion domains that are highly
expressed in various cancer lines. Covalent coupling of
DI17E6 onto DOX loaded albumin NPs showed inhibited
growth and angiogenesis in melanoma (Wagner et al., 2010).
Yu et al. (2016) described albumin NPs decorated with cyclic
arginine-glycine-aspartic (cRGD) peptides loaded with gemci-
tabine for the treatment of pancreatic cancer. The avb3
integrins specifically recognize the cRGD motif which sug-
gests the possibility of using cRGD-conjugated carriers to
deliver drugs into cancer cells as active tumor targeting ther-
apy. Finally, a sporopollenin-HSA (Sp-HSA) microparticle was
developed as a drug carrier. The Sp-HSA particles were
loaded successfully with DOX for targeted cancer treatment
(Maltas et al., 2016). To date, anti-cancer efficacy studies for
these Sp-HSA particles are lacking.
4.3.2. Covalent conjugations
Common strategies for direct, covalent conjugation involve
binding of the drug to either lysines, tyrosines or the free
SH-group on the cysteine-34 amino acid residue of albumin
(Larsen et al., 2016; Hoogenboezem & Duvall, 2018). HSA
methotrexate (HSA-MTX) is a covalent-bound MTX to lysine
residues in albumin. This conjugate was developed to
improve the pharmacokinetic profile of MTX. Methotrexate
conjugated at a 1:1 HSA:MTX ratio showed significant anti-
cancer efficacy in sarcoma as well as in prostate xenograft
models (Burger et al., 2001). A phase II clinical trial showed
that HSA-MTX in combination with cisplatin was effective
against urothelial carcinomas with an acceptable toxicity pro-
file (Hartung et al., 1999). However, no objective responses
were seen in patients with metastatic renal cell carcinoma
who had progressed after previous immunotherapy (Vis
et al., 2002). Similar to MTX, DOX was covalently conjugated
with lactosaminated human albumin (L-HSA) to increase its
efficacy in the treatment of hepatocellular carcinoma. The
anti-cancer efficacy of L-HSA-DOX was compared to unbound
DOX in a preclinical experiment. Compared to control rats
treated with saline, L-HSA-DOX significantly reduced the
number of neoplastic nodules, whereas the free DOX admin-
istered at the same dose was ineffective. Moreover, free DOX
markedly decreased the body weight of rats, a sign of sys-
temic toxicity, which was not caused by L-HSA-DOX (Di
Stefano et al., 2008). In 2014, Sun et al. (2014) reported a
BSA-CCM conjugate. The anti-cancer activity of free CCM and
BSA-CCM conjugate was assessed by an MTT assay on HeLa
cells. Only BSA-CCM conjugate showed significant inhibitory
effect against HeLa cells. Free CCM and its derivatives were
insoluble in water and could therefore not inhibit the growth
of HeLa cells. In contrast, BSA-CCM was readily soluble in
water amplifying the bioactivity against HeLa cells and inhib-
iting cellular proliferation.
4.3.3. Genetic fusions
Albumin fusion proteins are created by fuzing the gene that
expresses albumin to the gene that expresses a therapeutic-
ally active protein (Dou et al., 2008). Pruitt et al. (2016) pro-
duced a rHSA linked to the N-terminus of proaerolysin via a
peptide linker specific for the protease prostate specific anti-
gen. This pro-toxin can only be cleaved, and thus activated,
by a defined protease that is present in the prostate tumor
micro-environment. Recombinant interleukin-2 (rIL-2) is
thought to mediate anti-tumor cellular immune responses
through lymphocyte activation and is currently a therapy for
melanoma and renal cell carcinoma (Rosenberg, 2001). A rIL-
2 was genetically fused to rHSA creating the albuleukin
fusion protein. Albuleukin was introduced in clinical practice
to assess its therapeutic benefit in a variety of cancers
(Melder et al., 2005).
4.4. Transport mechanism of albumin-based drugs
Albumin is an important carrier protein with a number of
putative albumin-binding proteins and receptors that have
been identified in various tissues and cell lines. Table 3 pro-
vides a summary of albumin-binding proteins and receptors.
Unfortunately, there are relatively few papers studying the
cellular receptors of albumin and the significance of these
results were found to be mostly unclear (Merlot et al., 2014).
Consequently, further research is necessary to validate the
locations and functions of albumin-binding proteins and
receptors. This review will further focus on the transport
mechanisms of albumin-based drugs after IV and IP
administration.
4.4.1. IV Administration
Transport of albumin-based drugs after IV administration is
well described (Figure 6). Transcytosis of albumin across the
endothelium of blood vessels is mediated by gp60, a 60-kDa
glycoprotein localized on the endothelial cell surface that
binds albumin with high affinity in the nanomolar range. The
binding of albumin to gp60 induces gp60 clustering and
association with caveolin-1 (Cav-1), leading to the formation
of caveolae that will carry the albumin complexes from the
apical to the basal membrane, where the caveolae content is
released into the tumor interstitium. Binding of SPARC to
albumin causes release of free drug, which permeates into
tumor cells.
Receptor-mediated albumin uptake by cancer cells has
become evident based on the correlation between the
expression of albumin-related receptors and the efficacy of
albumin-bound drugs among different cancer types.
Chatterjee et al. attempted to demonstrate why certain
patients responded better to a treatment with Nab-PTX than
others. In preclinical in vivo experiments, Cav-1 protein levels
correlated positively with Nab-PTX sensitivity. RNAi-mediated
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attenuation of Cav-1 expression reduced uptake of albumin
and Nab-PTX in cancer cells and rendered them resistant to
Nab-PTX-induced apoptosis. Conversely, Cav-1 overexpres-
sion enhanced sensitivity to Nab-PTX (Chatterjee et al., 2017).
Zhao et al. (2018) further specified that higher tumor Cav-1
levels and lower stromal Cav-1 levels were significantly asso-
ciated with longer progression free survival of metastatic
breast cancer patients receiving Nab-PTX in combination
with gemcitabine. It has been hypothesized that the accumu-
lation of albumin in the tumor interstitium is facilitated by
Figure 6. Receptor-mediated transcytosis of albumin-based drugs after IV or IP administration.
Table 3. Overview of cellular receptors and ligand binding sites of albumin (Merlot et al., 2014; Chatterjee et al., 2017; Infante et al., 2007).
Albumin-binding proteins Tissue Function
cubilin Kidney, intestines, placenta, york-sac cells Endocytosis and transcellular transport of albumin;
reabsorption of albumin in kidney proximal
tubule cells
FcRn Endothelium, antigen-presenting cells, intestines, kidney,
lung, blood-brain-barrier
Protection of albumin from degradation in acidic
endosomes and returns albumin to the
extracellular space
gp18 Endothelium, macrophages, fibroblasts, tumor Bind and direct modified albumin for degradation
gp30 Endothelium, macrophages, fibroblasts, tumor Bind and direct modified albumin for degradation
gp60 Endothelium Internalization and transcytosis of albumin
hnRNP family Tumor Involved in pre-mRNA processing; cell adhesion,
modulation of platelet collagen interactions, apoptosis
(calreticulin)
megalin Kidney, intestines, placenta, york-sac cells, choroid plexus,
thyrocytes, epithelium, lung, parathyroid,
endometrium, oviduct, inner ear, epididymal cells
Contributes to the internalization of cubilin-ligand
complexes as a co-receptor; reabsorption of albumin
in kidney proximal tubule cells
SPARC Endothelial cells, vascular smooth muscle cells, skeletal
muscle, fibroblasts, testicle, ovary, pancreas, tumor
Accumulation of albumin-bound drugs within tumor
interstitium
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SPARC. This hypothesis was based on a clinical trial with
gemcitabine and Nab-PTX in patients with advanced pancre-
atic cancer. SPARC levels were evaluated in thirty-six patients.
An increase in SPARC levels was correlated with improved
overall survival. The significant increase in SPARC levels was
limited to the stroma and was not present in tumor cells
(Von Hoff et al., 2011). This finding suggested that the pres-
ence of SPARC in the tumor interstitium would concentrate
Nab-PTX and thus enhance its therapeutic effect. However,
other preclinical and clinical experiments showed no correl-
ation between SPARC levels and treatment efficacy
(Guweidhi et al., 2005; Infante et al., 2007; Hidalgo et al.,
2015; Chatterjee et al., 2017). Other albumin-binding proteins
and receptors that may mediate the accumulation of albu-
min-bound carriers in the tumor (interstitium) include gp18,
gp30, calreticulin, megalin, cubilin, heterogeneous nuclear
ribonucleoproteins (hnRNPs), and the neonatal Fc receptor
(FcRn) (Merlot et al., 2014).
4.4.2. IP administration
The peritoneal membrane is frequently considered to form a
barrier to albumin resorption. However, mechanistic analyses
have proven this assumption to be incorrect. Studies in
rodents and in dialysis patients have shown that proteins
leave the peritoneal cavity at rates 5–10 times the rate in
which it appears in plasma (Daugirdas et al., 1980; Flessner
et al., 1983; Kumano et al., 1996). Through dissection of
rodent tissues, it has been demonstrated that all the proteins
that left the peritoneal cavity but did not reach the plasma
were contained in the surrounding peritoneal tissues
(Flessner et al., 1983; Flessner & Schwab, 1996). In addition,
subsequent experiments showed that the rate of protein
transfer was quantitatively the same as the rate of fluid
transfer of an isotonic solution administered in the peritoneal
cavity (Flessner & Schwab, 1996). Moreover, the extent of
parietal peritoneal resection did not affect the pharmacokin-
etics of intraoperative IP chemotherapy illustrating that the
pharmacological barrier between the peritoneal cavity and
plasma is not directly related to an intact peritoneum (de
Lima Vazquez et al., 2003). Consequently, Flessner (2005)
concluded that the peritoneum is a very loose barrier.
The mechanisms and pathways governing the peritoneal
absorption of albumin from the peritoneal cavity have not
been completely identified (Figure 6). Gotloib & Shostak
(1995) injected healthy mice IP with BSA-gold particles to
assess transmesothelial absorption. A significant higher pro-
portion of the BSA-gold particles was detected in transcytotic
vesicles versus in intermesothelial junctions, supporting the
idea of a continuously transcytotic mechanism transporting
albumin across the mesothelial layer. In this sense, transcy-
totic vesicles could represent the large pore equivalent, simi-
lar to transport after IV administration. These findings are in
accordance with the experiments of Bodega et al. (2002)
who investigated the transport of albumin through the
mesothelium of parietal pericardium. Fresh retrosternal par-
ietal pericardium of rabbits was isolated and mounted as pla-
nar sheets in an Ussing chamber containing I125-albumin
solution. Thereafter, I125-albumin was detected in the
mesothelial cells of parietal pericardium by scintillation spec-
trometry. The results showed the occurrence of an active
transport of albumin from the luminal to the interstitial side
of the mesothelium. This active transport was due to transcy-
tosis. Moreover, the results demonstrated that transcytosis
decreases progressively at low albumin concentrations (Calb)
and eventually vanishes when Calb0.005%. Transcytosis
ceased when an inhibitor for transcytosis (40mM nocodazole)
was added to a 0.5% Calb solution. This suggests that the
vesicular transport is not constitutive but appears to be acti-
vated by albumin. Therefore, transmesothelial transport of
albumin-bound complexes probably occurs via transcytosis,
similar to transendothelial transport. The question arises
whether the mechanisms of albumin transcytosis in mesothe-
lium and endothelium utilize the same albumin-binding pro-
teins and signaling pathways. To our knowledge, nothing is
known about the mechanisms of cellular receptor-mediated
albumin transport in mesothelial cells.
The findings of Gotloib and Bodega were based on
experiments performed on healthy mesothelium, in which
the role of the intermesothelial cell junctions seemed to be
minor. This transport pathway may, however, become highly
permeable to anionic plasma proteins in a tumor tissue
environment. The tight junctions and basement membrane
are disrupted by exposure of the mesothelium to inflamma-
tory mediators such as hepatocyte growth factor (HGF).
Tumor cells induce apoptosis of the mesothelial cells leading
to an altered structure of the peritoneal membrane (Flessner,
2005; Ceelen & Bracke, 2009). This results in the peritoneum
becoming a looser barrier to albumin. Therefore, to unravel
the transport mechanisms of albumin-bound drugs after IP
administration, further research should also focus on intracel-
lular transport of albumin-bound drug in this specific
environment.
5. Efficacy of albumin-based drugs after IP
administration
Evidence for the efficacy of albumin-based drugs after IP
administration has been demonstrated for Nab-PTX, HSA-
MTX, rHSA-rIL-2 and HSA-Au NPs. Table 4 gives an overview
of the comparative preclinical experiments.
5.1. Nab-PTX
The taxanes are ideal candidates for IP administration due to
their activity profile and molecular size. Standard formulation
of PTX is highly hydrophobic and thus requires the use of
solvents such as Cremophor-EL, which contribute to some of
the toxicities commonly associated with PTX-based therapy
(Stinchcombe, 2007). Nab-PTX is a solvent-free formulation of
PTX. Binding PTX to albumin by high-pressure homogeniza-
tion of PTX in the presence of serum albumin into a NP col-
loidal suspension has several practical advantages over Sb-
PTX, such as the diminished need for premedication to pre-
vent hypersensitivity reactions. The Nab-PTX formulation
eliminates the impact of Cremophor-EL on PTX pharmacokin-
etics and utilizes the endogenous albumin transport
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mechanisms to concentrate Nab-PTX in the tumor, leading to
improved anti-cancer efficacy (Stinchcombe, 2007; Kinoshita
et al., 2014; Carlier et al., 2018).
Kinoshita et al. (2014) reported a comparative in vivo
study to evaluate the antitumor activity of Nab-PTX and Sb-
PTX after IP administration. Female athymic NCr-nu nude
mice were simultaneously inoculated with 1 107 OCUM-
2MD3 cells, a high peritoneal-seeding cell line from human
gastric cancer. The tumor-bearing mice were divided into
three groups: a control group, a Nab-PTX treatment group,
and a Sb-PTX treatment group. Antitumor activity was com-
pared among these three groups. After tumor inoculation on
day 0, drug treatment was initiated on day 7, and drug was
administered once daily for seven consecutive days at equi-
toxic doses. Nab-PTX treatment resulted in a significantly
higher antitumor activity compared to Sb-PTX treatment. All
five mice in the control group developed ascites and died
within 19–32 days after tumor cell inoculation, with a median
survival of 25 days. Animal survival was significantly better in
the Nab-PTX treatment group (median 126 days) compared
to that of the Sb-PTX treatment group (median 96 days).
These findings were in line with the results obtained by
Xiao et al. (2009). An orthotopic intraperitoneal model of
metastatic ovarian cancer was developed by injecting 1 107
luciferase positive SK-OV-3 cells IP into nude mice. Sb-PTX,
Nab-PTX or PBS (control) was intraperitoneally injected on
day 0, 4, 8, 12, and 16 at equitoxic doses. Bioluminescence
imaging was performed weekly after the treatment.
Strikingly, none of the mice treated with Sb-PTX demon-
strated complete response. Median overall survival was
39 days for untreated mice in the PBS control group, while
the Sb-PTX treated mice showed a median overall survival of
65 days. Therapy with Nab-PTX further prolonged the overall
survival to 81 days.
Similarly, the preclinical activity of Nab-PTX and polymeric
micellar PTX (mic-PTX) were tested in athymic nude Foxn1nu
mice (Carlier et al., 2018). All mice were bilaterally engrafted
in the subperitoneal space with 5 105 luciferase positive
SK-OV-3 cells to create peritoneal ovarian cancer xenografts.
Drug treatment was initiated 2 weeks after tumor cell inocu-
lation. The xenografts were then treated with repeated IP
injections of Nab-PTX, mic-PTX or saline (control). Both PTX
formulations significantly reduced the number and volume
of peritoneal tumor nodules and prolonged survival, com-
pared to the control group. The mitotic index was signifi-
cantly increased after IP Nab-PTX, but no difference was
observed between the IP mic-PTX group and the control
group. Four hours after IP injection, matrix-assisted laser
desorption/ionization (MALDI) imaging showed homoge-
neous and extensive tumor tissue penetration of Nab-PTX,
which was not observed in the mic-PTX treatment group.
Compared to mic-PTX, Nab-PTX lead to more pronounced
tumor penetration and tumor cell death. This may be
explained by the slow release in the peritoneal cavity of PTX
from the micellar formulation, since hydrophobic PTX tend
to remain in the hydrophobic core of polymeric micelles. In
contrast, Nab-PTX will more easily dissociate after IP adminis-
tration due to the reversible non-covalent binding (Miele
et al., 2009).
In a recent study using a hyperthermic IP chemotherapy
(HIPEC) model in the rabbit, Nab-PTX was compared to Sb-
PTX (Coccolini et al., 2017). Samples of perfusate and blood
were collected at different time points and peritoneal tissues
were collected at the end of perfusion. PTX after Nab-PTX
treatment penetrated up to 0.63mm in the peritoneal wall,
but after Sb-PTX, PTX was not detectable in the peritoneum.
Moreover, the peritoneal concentration after IP Nab-PTX
delivery was five times higher compared to Sb-PTX. Despite
the high levels reached in the peritoneum, systemic exposure
of PTX remained low.
IP catheter-based delivery of Nab-PTX was recently
studied in a phase I clinical trial in advanced carcinomatosis
Table 4. Efficacy of albumin-based drugs after IP administration.
Drugs Experimental setup Evidence after IP delivery References
Nab-PTX Mouse gastric cancer xenograft Survival was higher in the Nab-PTX treatment group (126 days)
compared to the Sb-PTX treatment group (96 days).
(Kinoshita et al., 2014)
Mouse ovarian cancer xenograft Survival was higher in the Nab-PTX treatment group (81 days)
compared to the Sb-PTX treatment group (65 days).
(Xiao et al., 2009)
Mouse ovarian cancer xenograft Nab-PTX led to more pronounced tumor penetration and tumor cell
death compared to mic-PTX.
(Carlier et al., 2018)
Non-tumor bearing rabbits PTX after Nab-PTX treatment penetrated up to 0.63mm in the
peritoneal wall, but after Sb-PTX, PTX was not detectable in the
peritoneum. The peritoneal concentration after IP Nab-PTX
delivery was five times higher compared to Sb-PTX.
(Desai, 2016)
HSA-MTX Mouse soft tissue sarcoma xenograft A single IP injection of MTX-HSA caused complete tumor remission
for more than 119 days. Repeated IV injections of MTX resulted in
short-lasting partial tumor regression.
(Burger et al., 2001)
Mouse prostate cancer xenograft MTX-HSA showed tumor growth inhibition of 92.8% compared to
the control mice, while injection of MTX showed growth
inhibition of 20.8% compared to the control mice.
(Burger et al., 2001)
rHSA-rIL-2 Mouse renal cancer allograft Tumor volume was decreased to 280mm3 in the rHSA-rIL-2
treatment group, compared to 1320mm3 in the rIL-2 treatment
group. The survival of the treatment groups was similar.
(Melder et al., 2005)
HSA-Au NPs Mouse colon cancer allograft Accumulation of Au-HSA NPs in the peritoneal cavity and tumor
lesion after IP injection was higher, compared to IV injection.
After IP injection, AUC of ascites and tumor were respectively 93-
and 20-fold higher, while the AUC of liver and spleen were
respectively 12- and 11-fold lower, compared to IV injection.
(Chen et al., 2019)
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patients to determine the maximal tolerated dose (MTD)
(Cristea et al., 2019). Nab-PTX was administered weekly on
days 1, 8, and 15 of a 28-day cycle in successive cohorts of
patients with no intra-patient dose escalation. Doses
explored were 35, 70, 90, 112.5, 140, and 175mg/m2. No
dose-limiting toxicities (DLTs) were observed in dose levels
35, 70, and 90mg/m2. A DLT was noticed in one of six
patients in dose level 112.5mg/m2 (grade 3 neutropenia
causing more than 15 days treatment delay) and a DLT in
one of three patients allocated to dose level 175mg/m2
(grade 4 neutropenia and grade 3 abdominal pain). A second
patient in dose level 175mg/m2 experienced a serious
adverse event (cycle 1 grade 4 neutropenia less than 7 days,
cycle 4 grade 2 left ventricular dysfunction). This dose level
was determined to be above the MTD. No DLTs were seen in
all patients treated with 140mg/m2 Nab-PTX. Therefore, the
MTD of IP Nab-PTX was established at 140mg/m2. A signifi-
cant pharmacokinetic advantage of IP Nab-PTX was found at
each dose level. Across all dose levels of Nab-PTX, the
median IP versus IV AUC was 147-fold, resulting in increased
peritoneal drug exposure. Eight of twenty-seven enrolled
patients showed a progression free survival of more than
6 months. One patient experienced a complete response,
and one patient experienced a partial response. Six patients
had stable disease.
Recently, the technique of laparoscopic (pressurized) IP
aerosol chemotherapy (PIPAC) was introduced in clinical
practice (Solass et al., 2014; Grass et al., 2017). During lapar-
oscopy, chemotherapy is delivered as an aerosol, generated
by a dedicated micropump connected to a high-pressure
injector. Advantages of PIPAC include minimal patient dis-
comfort, the possibility of repeated delivery, the potential to
combine it with systemic treatment, and the possibility to
assess pathological response of peritoneal disease by serial
biopsies. In theory, any cancer drug may be delivered IP as
an aerosol. A multicenter, first-in-human phase 1 dose escal-
ation study to explore the safety of PIPAC using Nab-PTX in
patients with unresectable peritoneal metastasis was initiated
(NCT03304210) (Van De Sande et al., 2018). Patients will
undergo three consecutive PIPAC procedures with an interval
of 4 weeks. The dose levels of Nab-PTX are 35, 70, 90, 112.5,
and 140mg/m2. The same dose will be used for all three
treatments in the same patients.
5.2. HSA-MTX
After IV administration, MTX is rapidly and efficiently cleared
from the circulation. The mean distribution half-life ranges
from 1.5 to 3.5 h in patients with normal total body clearance
(Evans et al., 1986). Consequently, tumor exposure time of
MTX is short, and a HSA-MTX conjugate was introduced to
prolong exposure. A comparative in vivo study examined the
antitumor activity of HSA-MTX (12.5mg/kg) after IP adminis-
tration versus IV administration of unbound MTX (100mg/kg)
(Burger et al., 2001). A soft tissue sarcoma xenograft (SXF
1301) and a prostate-cancer xenograft (PRXF PC3M) were
used. Tumor fragments of 25mg were subcutaneously (SC)
implanted in both flanks of outbred nude mice. When
tumors were clearly palpable and had reached a volume of
100–200mm3, mice were randomly allocated into treatment
groups and were weekly treated for 3 weeks. In the soft tis-
sue sarcoma xenograft, a single IP injection of MTX-HSA was
sufficient to cause complete tumor remission for more than
119 days (end of experiment) after treatment was initiated.
Therefore, injections on days 8 and 15 were not given. IV
MTX was less effective and resulted in only short-lasting par-
tial tumor regression. In the prostate-cancer xenograft, MTX-
HSA showed tumor growth inhibition of 92.8% compared to
the control mice, while injection of MTX showed growth
inhibition of 20.8% compared to the control mice.
5.3. rHSA-rIL-2
Interleukin-2 is thought to mediate antitumor cellular
immune responses through lymphocyte activation, and is
currently approved for the IV treatment of melanoma and
renal cell carcinoma (Rosenberg, 2001). However, the short
half-life of rIL-2 and its systemic toxicity continue to limit the
clinical use of this recombinant protein (Lotze et al., 1985).
Albumin fusion technology provides the advantageous phar-
macokinetic properties of albumin to a fusion partner such
as rIL-2, resulting in a new protein with improved thera-
peutic potential. The pharmacological activity of rHSA-rIL-2
was examined in female BALB/c mice to determine whether
the fusion protein had the immunomodulatory and antitu-
mor properties of rIL-2 (Melder et al., 2005). On day 0, mice
were inoculated SC in the midflank region with 1 105
Renca cells, a murine renal carcinoma cell line. Mice received
daily IP injections of rIL-2 (0.9mg/kg) on days 10–14 and
17–21. Control mice received daily IP injections with PBS on
the same days. The effect of rHSA-rIL-2 (0.6mg/kg) was eval-
uated by IP injection on days 12, 14, 16, 19, 21, and 23.
Tumor volume was measured on day 28 using millimetre-
calibrated calipers and mice were monitored for survival on
a daily basis until 40 days post-inoculation. On day 28,
median tumor volume was 3200mm3 in the control group,
while the rIL-2 treated mice showed a non-significant
decrease to a median volume of 1320mm3. The median
tumor volume further decreased to 280mm3 in rHSA-rIL-2
treated mice, which was significantly smaller compared to
the control group. In addition, three of ten mice treated with
rHSA-rIL-2 were either tumor-free or had minimally detect-
able tumor (<1mm3) compared to zero of ten mice in the
control group. Four out of ten control mice survived until
day 28 while all mice receiving rHSA-rIL-2 survived. The sur-
vival benefit after IP treatment of rIL-2 was similar to that of
rHSA-rIL-2.
5.4. HSA-Au NPs
Hybrid protein-inorganic NP systems have displayed multi-
functional applications in solid cancer theranostics (An et al.,
2014; An & Zhang, 2017). However, the potential of these
NPs for treating peritoneal metastases remains unclear. Chen
et al. developed a gold nanocore-encapsulated HSA (Au-HSA)
NP as a drug delivery system (Chen et al., 2019). Its
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radioactive surrogate Indium-111 labeled Au-HSA (111In-Au-
HSA) was prepared to investigate the biological behavior in
a CT-26 colon tumor/ascites-bearing mouse model. Male
BALB/c mice were inoculated intraperitoneally with 2 105
CT-26 cells, a murine colon carcinoma cell line. Ten to
14 days after tumor cell inoculation, mice received 111In-Au-
HSA NPs by either an IV or IP injection. Both biodistribution
and microSPECT imaging exhibited a significant accumula-
tion of 111In-Au-HSA NPs in the peritoneal cavity and tumor
lesion after IP injection, compared to IV injection. After IP
injection, AUC of ascites and tumor were respectively 93-
and 20-fold higher, while the AUC of liver and spleen were
respectively 12- and 11-fold lower, compared to IV injection.
This study demonstrated that Au-HSA NPs are a potential IP
drug delivery system in the treatment of peritoneal metasta-
sis. Future goals should be the encapsulation of cytostatic
drugs in the Au-HSA NPs to perform in vitro and in vivo
anti-cancer efficacy studies.
6. Conclusions and future perspectives
Intraperitoneal therapy for PM is a rapidly growing field.
Results from recent preclinical and clinical trials have shown
a superior efficacy of IP delivery of albumin-bound chemo-
therapy in the treatment of PM compared to standard
chemotherapy formulations. Targeted delivery of chemother-
apy is enabled by albumins’ inherent transport properties.
Transmesothelial transport of albumin-bound complexes
occurs via transcytosis, similar to transendothelial transport.
The mechanisms mediating albumin transcytosis in mesothe-
lial cells are not fully elucidated. Therefore, future research
should focus on the presence of albumin-binding receptors,
mechanisms of albumin transcytosis, and formation of trans-
cytotic vesicles in mesothelial cells. Also, efforts should be
made to identify the mechanisms and kinetics of IP albumin-
drug dissociation, and to correlate these with pharmacoki-
netic and pharmacodynamic models, in vivo toxicity, and
anti-cancer efficacy. Knowledge of these mechanisms will
allow to develop informed designs for further early phase
clinical trials using IP albumin-based drug delivery in patients
with PM.
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